Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Boston, Massachusetts

This page shows live ClinicalTrials.gov search results for Boston, Massachusetts, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
21483
Shown on this page
12
Current sort
Recently updated
Location scope
Boston, MA
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Boston, Massachusetts. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 217–228 of 21,483 matching trials in Boston, MA.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Boston

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 2 Interventional

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT07142356
View directory record Official record
Conditions
Uncontrolled Hypertension
Interventions
RTN-001, Matching placebo control
Drug
Lead sponsor
Retension Pharmaceuticals. Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
44
States / cities
Alexander City, Alabama • Birmingham, Alabama • Glendale, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)

NCT05099003
View directory record Official record
Conditions
Malignant Glioma
Interventions
Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
111
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 93 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer

NCT05296512
View directory record Official record
Conditions
Ovarian Clear Cell Carcinoma, Gynecologic Cancer
Interventions
Lenvatinib, Pembrolizumab
Drug
Lead sponsor
Elizabeth K. Lee MD
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Recruiting Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT06588478
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pirtobrutinib
Drug
Lead sponsor
Loxo Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
20
States / cities
Chandler, Arizona • Duarte, California • Irvine, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Active, not recruiting Phase 1 Interventional

Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome

NCT04652960
View directory record Official record
Conditions
Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Duvelisib, Nivolumab, Positron Emission Tomography, Punch Biopsy
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Not yet recruiting Phase 3 Interventional

The Study of Brave-LC LDN Treatment Trial

NCT07916259
View directory record Official record
Conditions
Post-acute COVID-19 Syndrome
Interventions
naltrexone, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Years to 25 Years
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Birmingham, Alabama • Chula Vista, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Enrolling by invitation No phase listed Observational

Registry of Patients With Hypophosphatasia

NCT02306720
View directory record Official record
Conditions
Hypophosphatasia (HPP)
Interventions
Not listed
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
1,571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2031
U.S. locations
20
States / cities
Centennial, Colorado • Hartford, Connecticut • Tampa, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

NCT04811560
View directory record Official record
Conditions
Acute Leukemia
Interventions
Bleximenib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
2 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
26
States / cities
Duarte, California • Orange, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Recruiting No phase listed Observational

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180
View directory record Official record
Conditions
Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Interventions
Device
Device
Lead sponsor
Medtronic
Industry
Eligibility
Not listed
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1983 – 2040
U.S. locations
114
States / cities
Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Completed Phase 2 Interventional

A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

NCT05379634
View directory record Official record
Conditions
Myositis
Interventions
Nipocalimab, Placebo, Glucocorticoids
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
19
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Recruiting Phase 2 Interventional

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

NCT07186101
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
LY4268989, Mirikizumab, LY4268989 Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
40
States / cities
Scottsdale, Arizona • Anaheim, California • Lancaster, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST
Recruiting Phase 2Phase 3 Interventional

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723
View directory record Official record
Conditions
Symptomatic Genetic Dilated Cardiomyopathy
Interventions
danicamtiv, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2026 · Synced Nov 6, 2026, 5:29 PM EST